The cell and gene therapy contract development and manufacturing organization (CDMO) market is projected to grow at a compound annual growth rate (CAGR) of approximately 24% from 2026 to 2034, reaching a market size of $57.1 billion by 2034. Growth is driven by increasing clinical development of cell and gene therapies, rising investments in regenerative medicine, CAR-T therapies, and gene editing technologies, and the need for specialized manufacturing services. North America currently leads the market, supported by advanced biotech infrastructure and regulatory support, while Europe and Asia-Pacific regions are also expanding rapidly due to growing biotech ecosystems and government incentives. Key players like Catalent, Lonza, and Thermo Fisher are expanding partnerships and manufacturing capabilities to meet rising demand for commercial-scale production and integrated development services.
